Study shows Amiodarone loses to ablation for the treatment of refractory form of VT
SAN FRANCISCO A study presented at a late-breaking clinical trial session at the Heart Rhythm Society annual meeting suggests that patients who are already on amiodarone now have a choice of drug and device therapy if their current dosage level fails to keep their ventricular tachycardia (VT) under control.
Boston Scientific flies the W flag
It took 10 years but Boston Scientific (BSX) may have finally overcome its ill-advised 2006 Guidant acquisition. The company's shares hit a decade high Wednesday, at one point spiking nearly 12 percent to $22.05 after knocking its first quarter sales out of the park. (MDD Perspectives)
Growing evidence supports clinical potential of new cancer tests
With a market opportunity in the billions (as much as $20 billion by some estimates), diagnostic companies are rushing the liquid biopsy floodgates with new tests designed to make finding and monitoring cancer as easy as a blood draw or urine sample. This week, in a two-part series, Medical Device Daily will explore both the business opportunities and the clinical potential of this growing market.